Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments

International Journal for Parasitology Drugs and Drug Resistance(2023)10.1016/j.ijpddr.2023.01.003Source: DataRank Database

Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments is a research paper published in International Journal for Parasitology Drugs and Drug Resistance (2023). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.41)OA: goldTopics (34)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Sevan N. Alwan ORCID,Susan Khan,Stanton F. McHardy ORCID,Philip T. LoVerde ORCID,Michael D. Cameron ORCID

Live enrichment

PubMed:36758271 PMC:PMC9929523 OpenAlex:https://openalex.org/W4318464620

National Institutes of Health Office of the Director

Grant: 1S10OD030332

National Institute of General Medical Sciences

Grant: 2K12GM111726

NIGMS NIH HHS

Grant: K12 GM111726

NIH HHS

Grant: S10 OD030332

NIH HHS

Grant: S10 OD010603

National Institutes of Health

Morrison Trust

FWCI

1.41

Citation Percentile

0.8%

Citation Trend

2024

2025

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ijpddr.2023.01.003

publisherhttps://doi.org/10.1016/j.ijpddr.2023.01.003

publisherhttps://api.elsevier.com/content/article/PII:S2211320723000039?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211320723000039?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36758271

Fields of Study

Parasites and Host InteractionsPharmacological Effects and Toxicity StudiesHelminth infection and controlHumansMiceAnimalsOxamniquineSchistosomaSchistosomicidesSchistosoma mansoni

MeSH Terms

AnimalsHumansOxamniquineSchistosomaSchistosoma mansoniSchistosomicidesMice

Keywords

In vivoIn vitroSchistosoma mansoniPharmacologyPharmacokineticsGlucuronateChemistryBioavailabilityOxamniquinePraziquantelBiologyBiochemistryImmunologySchistosomiasisSchistosomeParasitic WormPk/pd Relationship

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis

10.6084/m9.figshare.25658563.v1figshare

Additional file 1 of Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis

10.6084/m9.figshare.25658563figshare

Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments

FAIR Checklist

Authors (6)

Funding (7 grants)

Impact

Open Access

Topics

Linked Datasets (2)

Annotations (Europe PMC)